Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardio‐<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardio‐<scp>O</scp>ncology <scp>S</scp>ociety

  • Alexander R. Lyon
    Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
  • Susan Dent
    Duke Cancer Institute Duke University Durham NC USA
  • Susannah Stanway
    Breast Unit Royal Marsden Hospital Surrey UK
  • Helena Earl
    Department of Oncology University of Cambridge and NIHR Cambridge Biomedical Research Centre Cambridge UK
  • Christine Brezden‐Masley
    Division of Medical Oncology, Sinai Health System Mount Sinai Hospital Toronto Canada
  • Alain Cohen‐Solal
    UMR‐S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP‐HP Paris France
  • Carlo G. Tocchetti
    Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET) Federico II University Naples Italy
  • Javid J. Moslehi
    Cardio‐Oncology Program, Department of Medicine Vanderbilt University Medical Center Nashville TN USA
  • John D. Groarke
    Cardio‐Oncology Program, Brigham & Women's Hospital Harvard Medical School Boston MA USA
  • Jutta Bergler‐Klein
    Department of Cardiology Medical University of Vienna Vienna Austria
  • Vincent Khoo
    Department of Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research London UK
  • Li Ling Tan
    Department of Cardiology, National University Heart Centre, Singapore National University Health System Singapore Singapore
  • Markus S. Anker
    Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany
  • Stephan von Haehling
    Department of Cardiology and Pneumology University of Goettingen Medical Center Goettingen Germany
  • Christoph Maack
    Comprehensive Heart Failure Center University Clinic Würzburg Würzburg Germany
  • Radek Pudil
    First Department of Medicine – Cardioangiology, Charles University Prague Medical Faculty and University Hospital Hradec Kralove Prague Czech Republic
  • Ana Barac
    MedStar Heart and Vascular Institute Georgetown University Washington DC USA
  • Paaladinesh Thavendiranathan
    Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital University Health Network, University of Toronto Toronto Canada
  • Bonnie Ky
    University of Pennsylvania Philadelphia PA USA
  • Tomas G. Neilan
    Cardio‐Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital Harvard Medical School Boston MA USA
  • Yury Belenkov
    Sechenov Medical University Moscow Russia
  • Stuart D. Rosen
    Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
  • Zaza Iakobishvili
    Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
  • Aaron L. Sverdlov
    School of Medicine and Public Health, University of Newcastle and “Cancer and the Heart” Program Hunter New England LHD Newcastle Australia
  • Ludhmila A. Hajjar
    Cardio‐Oncology, Department of Cardio‐Pneumology University of São Paulo São Paulo Brazil
  • Ariane V.S. Macedo
    Santa Cardio‐Oncology, Santa Casa de São Paulo and Rede Dor São Luiz São Paulo Brazil
  • Charlotte Manisty
    Barts Heart Centre and University College London London UK
  • Fortunato Ciardiello
    Department of Precision Medicine Luigi Vanvitelli University of Campania Naples Italy
  • Dimitrios Farmakis
    University of Cyprus Medical School Nicosia Cyprus
  • Rudolf A. de Boer
    Department of Cardiology University of Groningen, University Medical Center Groningen Groningen The Netherlands
  • Hadi Skouri
    Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center Beirut Lebanon
  • Thomas M. Suter
    Department of Cardiology, Bern University Hospital, Inselspital University of Bern Bern Switzerland
  • Daniela Cardinale
    Cardioncology Unit, European Institute of Oncology IRCCS Milan Italy
  • Ronald M. Witteles
    Stanford University School of Medicine Stanford CA USA
  • Michael G. Fradley
    University of Pennsylvania Philadelphia PA USA
  • Joerg Herrmann
    Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA
  • Robert F. Cornell
    Vanderbilt University Medical Center Nashville TN USA
  • Ashutosh Wechelaker
    National Amyloidosis Centre University College London London UK
  • Michael J. Mauro
    Memorial Sloan Kettering Cancer Center New York NY USA
  • Dragana Milojkovic
    Department of Haematology Hammersmith Hospital, Imperial College London UK
  • Hugues de Lavallade
    Department of Haematological Medicine King's College Hospital London UK
  • Frank Ruschitzka
    University Heart Center, Department of Cardiology University Hospital Zurich Zurich Switzerland
  • Andrew J.S. Coats
    University of Warwick Warwick UK
  • Petar M. Seferovic
    Faculty of Medicine and Serbian Academy of Sciences and Arts University of Belgrade Belgrade Serbia
  • Ovidiu Chioncel
    Emergency Institute for Cardiovascular Diseases ‘Prof. C.C. Iliescu’ Bucharest Romania
  • Thomas Thum
    Institute of Molecular and Translational Therapeutic Strategies Hannover Medical School Hannover Germany
  • Johann Bauersachs
    Department of Cardiology and Angiology Hannover Medical School Hannover Germany
  • M. Sol Andres
    Cardio‐Oncology Service Royal Brompton Hospital and Imperial College London UK
  • David J. Wright
    Liverpool Centre for Cardiovascular Science Liverpool Heart and Chest Hospital Liverpool UK
  • Teresa López‐Fernández
    Cardiology Service, Cardio‐Oncology Unit La Paz University Hospital and IdiPAz Research Institute, Ciber CV Madrid Spain
  • Chris Plummer
    Department of Cardiology The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University Newcastle UK
  • Daniel Lenihan
    Cardio‐Oncology Center of Excellence Washington University in St Louis St Louis MO USA

抄録

<jats:p>This position statement from the Heart Failure Association of the European Society of Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio‐Oncology Society presents practical, easy‐to‐use and evidence‐based risk stratification tools for oncologists, haemato‐oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2‐targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi‐targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR‐ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ